Quantification of polyclonal free light chains in clinical samples using a single turbidimetric immunoassay

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 11, 2014, Pages 1605-1613

  Faint, Jeffrey M ^a   Basu, Supratik ^b   Sutton, David ^b   Showell, Paul J ^a   Kalra, Philip A ^c   Gunson, Bridget K ^d   Jackson, Colette E ^e   Mushtaq, Adeel ^a   Assi, Lakhvir K ^a   Carr Smith, Hugh D ^a   Cockwell, Paul ^f,g   Harding, Stephen J ^a,g  

^a Binding Site Group Ltd   (United Kingdom)

^b ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

free light chains; immune response; immunoassay; immunology; renal insufficiency

Indexed keywords

FREE LIGHT CHAIN; FREE LIGHT CHAIN KAPPA; FREE LIGHT CHAIN LAMBDA; IMMUNOGLOBULIN LIGHT CHAIN; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; BILIRUBIN; HEMOGLOBIN; LATEX; MICROSPHERE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; B LYMPHOCYTE ACTIVATION; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; MORTALITY; OVERALL SURVIVAL; PREDICTIVE VALUE; QUANTITATIVE ASSAY; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME; TURBIDIMETRY; ALCOHOL LIVER DISEASE; ANIMAL; BLOOD; BLOOD ANALYSIS; CHEMISTRY; HEART FAILURE; HEMATOLOGIC DISEASE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOTOMETRY; PROCEDURES; REFERENCE VALUE; SHEEP; STANDARDS; SURVIVAL RATE;

AGED; ANIMALS; ANTIBODIES; BILIRUBIN; BLOOD CHEMICAL ANALYSIS; HEART FAILURE; HEMATOLOGIC DISEASES; HEMOGLOBINS; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN LIGHT CHAINS; LATEX; LIVER DISEASES, ALCOHOLIC; MICROSPHERES; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; REFERENCE VALUES; SHEEP; SURVIVAL RATE;

EID: 84908093966     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0279     Document Type: Article

References (40)

1. Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 2008;28:205-15
2. Campbell KA, Lipinski MJ, Doran AC, Skaflen MD, Fuster V, McNamara CA. Lymphocytes and the adventitial immune response in atherosclerosis. Circ Res 2012;110:889-900
3. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy 1969;13:1-110
4. Solling K. Free light chains of immunoglobulins. Scand J Clin Lab Invest Suppl 1981;157:1-83
5. Abe M, Goto T, Kosaka M, Wolfenbarger D, Weiss DT, Solomon A. Differences in kappa to lambda (κ:δ) ratios of serum and urinary free light chains. Clin Exp Immunol 1998;111:457-62
6. Abraham GN, Waterhouse C. Evidence for defective immunoglobulin metabolism in severe renal insufficiency. Am J Med Sci 1974;268:227-33
7. Epstein WV, Tan M. Increase of L-chain proteins in the sera of patients with systemic lupus erythematosus and the synovial fluids of patients with peripheral rheumatoid arthritis. Arthritis Rheum 1966;9:713-9
8. Brouwer J, Otting-van de Ruit M, Busking-van der Lely H. Estimation of free light chains of immunoglobulins by enzyme immunoassay. Clin Chim Acta 1985;150:267-74
9. Robinson EL, Gowland E, Ward ID, Scarffe JH. Radioimmunoassay of free light chains of immunoglobulins in urine. Clin Chem 1982;28:2254-8
10. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80
11. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24
12. Anandram S, Assi LK, Lovatt T, Parkes J, Taylor J, MacWhannell A, et al. Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK study. J Clin Pathol 2012;65:1036-42
13. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Therneau TM, Colby CL, et al. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc 2012;87:517-23
14. Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan A, et al. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res 2011;63:891-8
15. Kormelink TG, Tekstra J, Thurlings RM, Boumans MH, Vos K, Tak PP, et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann Rheum Dis 2010;69:2137-44
16. Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C, Rizzardini G, et al. Role of serum free light chains in predicting HIVassociated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Am J Hematol 2012;87:749-53
17. Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010;28:773-9
18. Maurer MJ, Cerhan JR, Katzmann JA, Link BK, Allmer C, Zent CS, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood 2011;118:2821-6
19. Haynes R, Hutchison CA, Emberson J, Dasgupta T, Wheeler DC, Townend JN, et al. Serum free light chains and the risk of ESRD and death in CKD. Clin J Am Soc Nephrol 2011;6:2829-37
20. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free κand free δimmunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44
21. Tholen DW, Kroll M, Astles JR, Caffo AL, Happe TM, Krouwer J, et al. Evaluation of the linearity of quantitative measurement procedures; a statistical approach, approved guideline. CLSI document EP6-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2003
22. Tholen DA, Kallner A, Kennedy JW, Krouwer JS, Meier K. Evaluation of precision performance of quantitative measurement methods; approved guideline. 2nd ed. CLSI document EP5-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2004
23. Taylor J. An introduction to error analysis. Oxford: Oxford University Press, 1982
24. McEnroe R, Burrit M, Powers D, Rheinheimer D, Wallace B. Interference testing in clinical chemistry; approved guideline. 2nd ed. CLSI document EP7-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2013
25. Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O'Donoghue DJ, et al. Factors associated with kidney disease progression and mortality in a referred CKD population. Am J Kidney Dis 2010;56:1072-81
26. Jackson CE, Myles RC, Tsorlalis IK, Dalzell JR, Rocchiccioli JP, Rodgers JR, et al. Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. Eur J Heart Fail 2013;15:1253-61
27. Bibas M. Polyclonal serum free light chains: a biomarker of disease prognosis or of immune senescence? J Clin Oncol 2012;30:3033-4
28. Hutchison CA, Landgren O. Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation. Clin Chem 2011;57:1387-9
29. Assi LK, Hughes RG, Gunson B, Webb G, Adams DH. Polyclonally raised serum free light chains in liver disease compared to markers of liver damage. Hematology Reports 2010;2:47
30. Kurt IH, Yavuzer K, Batur MK. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure. Heart Vessels 2010;25:392-9
31. Assi L, McIntyre NJ, Hutchison CA, Hughes R, Stringer S, Fluck RJ, et al. Total serum free light chains independently predict survival in patients with stage 3 chronic kidney disease. J Am Soc Nephrol 2011;22:449a
32. Miettinen TA, Kekki M. Effect of impaired hepatic and renal function on [131I] Bence Jones protein catabolism in human subjects. Clin Chim Acta 1967;18:395-407
33. Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest 1972;51:2162-74
34. Hutchison CA, Harding S, Bevins A, Stringer SJ, Cockwell P. Polyclonal immunoglobulin free light chain concentrations and survival in patients with renal disease. J Am Soc Nephrol 2011;22:156a
35. Assi L, Young P, Hughes R, Hutchison CA. Total serum free light chains are an important prognostic marker in patients with type II diabetes. J Am Soc Nephrol 2011;22:229a
36. Hutchinson AT, Jones DR, Raison RL. The ability to interact with cell membranes suggests possible biological roles for free light chain. Immunol Lett 2012;142:75-7
37. Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA. Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci 2008;29:170-4
38. Braber S, Thio M, Blokhuis BR, Henricks PA, Koelink PJ, Groot KT, et al. An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:817-24
39. Cohen G, HÖrl WH. Free immunoglobulin light chains as a risk factor in renal and extrarenal complications. Semin Dial 2009;22:369-72
40. Brebner JA, Stockley RA. Polyclonal free light chains: a biomarker of inflammatory disease or treatment target? F1000 Med Rep 2013;5:4.